An FDA advisory committee has voted to restrict indications for testosterone replacement therapy and require additional clinical trials to test the safety of the drugs, decisions that have drawn mixed reactions from urologists.
The Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.
Ultrasound should be the initial diagnostic imaging test utilized for diagnosing kidney stones in order to reduce the higher radiation exposure associated with computed tomography, say the authors of a recent study.
The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
The month of September has seen two notable appointments in academic urology, with David F. Penson, MD, MPH, and James McKiernan, MD, both named to department chair positions.